Standaryzowana kompozycja polifenoli z bergamoty – kompleksowy suplement diety o właściwościach plejotropowych na tle innych dostępnych na rynku wybranych naturalnych substancji hipolipemizujących Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2021
Słowa kluczowe:
standaryzowana kompozycja polifenoli z bergamoty, dyslipidemia, właściwości plejotropowe
##plugins.themes.bootstrap3.article.main##
Abstrakt
Sok bergamotowy charakteryzuje się unikatowym profilem flawonoidów. Jest szczególnie bogaty we flawanony i flawony. Standaryzowana kompozycja polifenoli z bergamoty zawiera flawonoidy takie jak sok bergamotowy, jednak ponad 200 razy bardziej skoncentrowane. Liczne dane wskazują na jej znakomite działanie w hiperlipidemii i umiarkowanej hiperglikemii. Ponadto, na tle innych dostępnych na rynku suplementów diety, wykazuje ona korzystne właściwości plejotropowe.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Barylski , M. (2021). Standaryzowana kompozycja polifenoli z bergamoty – kompleksowy suplement diety o właściwościach plejotropowych na tle innych dostępnych na rynku wybranych naturalnych substancji hipolipemizujących. Medycyna Faktów , 14(1(50), 36-41. https://doi.org/10.24292/01.MF.0121.4
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Podbielkowski Z. Słownik roślin użytkowych. PWRiL, Warszawa 1989.
2. Nogata Y, Sakamoto K, Shiratsuchi H et al. Flavonoid composition of fruit tissues of citrus species. Biosci Biotechnol Biochem. 2006; 70: 178-92.
3. Di Donna L, De Luca G, Mazzotti F et al. Statin-like principles of bergamot fruit (Citrus bergamia): isolation of 3-hydroxymethylglutaryl flavonoid glycosides. J Nat Prod. 2009; 72: 1352-4.
4. Hwang JT, Kwon DY, Yoon SH. AMP-activated protein kinase: a potential target for the diseases prevention by natural occurring polyphenols. N Biotechnol. 2009; 26: 17-22.
5. Leopoldini M, Malaj N, Toscano M et al. On the inhibitor effects of bergamot juice flavonoids binding to the 3-hydroxy-3-methylglu-taryl-CoA reductase (HMGR) enzyme. J Agric Food Chem. 2010: 58; 10768-73.
6. Mollace V, Sacco I, Janda E et al. Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitoterapia. 2011; 82: 309-16.
7. Capomolla AS, Janda E, Paone S et al. Atherogenic Index Reduction and Weight Loss in Metabolic Syndrome Patients Treated with A Novel Pectin- Enriched Formulation of Bergamot Polyphenols Nutrients. 2019; 11(6): 1271.
8. Gliozzi M, Walker R, Muscoli S et al. Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. Int J Cardiol. 2013; 170(2): 140-5.
9. Gliozzi M, Carresi C, Musolino V et al. The Effect of Bergamot-Derived Polyphenolic Fraction on LDL Small Dense Particles and Non Alcoholic Fatty Liver Disease in Patients with Metabolic Syndrome. Adv Biol Chem. 2014; 4: 129-37.
10. Mollace V, Malara N, Gratteri S et al. Bergamot polyphenolic fraction counteracts erectile dysfunction occurring in patients suffering from type 2 diabetes. PharmaNutrition. 2016; 4S: S41-S6.
11. Lauro F, Ilari S, Giancotti LA et al. The protective role of bergamot polyphenolic fraction on several animal models of pain. PharmaNutrition. 2016; 4S: S35-S40.
12. Nisticò SP, Bottoni U, Gliozzi M et al. Bergamot polyphenolic fraction counteracts photoageing in human keratinocytes. PharmaNutrition. 2016; 4S: S32-S4.
13. Carresi C, Gliozzi M, Giancotta C et al. Studies on the protective role of Bergamot polyphenols in doxorubicin-induced cardiotoxicity. Pharma- Nutrition. 2016; 4S: S19-S26.
14. Lin CC, Li TC, Lai MM. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol. 2005; 153: 679-86.
15. Mamcarz A, Barylski M, Wełnicki M (ed). Lipidologia. Wydawnictwo Lekarskie PZWL, Warszawa 2021.
16. Musa‑Veloso K, Poon TH, Elliot JA et al. A comparison of the LDL‑cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta‑analysis of randomized, placebo‑controlled trials. Prostaglandins Leukot Essent Fatty Acids. 2011; 85: 9-28.
17. Pirro M, Vetrani C, Bianchi C et al. Joint position statement on „Nutraceuticals for the treatment of hypercholesterolemia” of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA). Nutr Metab Cardiovasc Dis. 2017; 27: 2-17.
18. Reiner Z, Tedeschi‑Reiner E, Romic Z. Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and C‑reactive protein in hypercholesterolaemic patients. Clin Drug Investig. 2005; 25: 701-7.
19. Lan J, Zhao Y, Dong F et al. Meta‑analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015; 161: 69-81.
20. Dewell A, Hollenbeck PL, Hollenbeck CB. Clinical review: a critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations. J Clin Endocrinol Metab. 2006; 91: 772-80.
21. Sahebkar A, Pirro M, Banach M et al. Lipid-lowering activity of artichoke extracts: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2018; 58(15): 2549-56.
22. Ried K, Toben C, Fakler P. Effect of garlic on serum lipids: an updated meta-analysis. Nutr Rev. 2013; 71: 282-99.
2. Nogata Y, Sakamoto K, Shiratsuchi H et al. Flavonoid composition of fruit tissues of citrus species. Biosci Biotechnol Biochem. 2006; 70: 178-92.
3. Di Donna L, De Luca G, Mazzotti F et al. Statin-like principles of bergamot fruit (Citrus bergamia): isolation of 3-hydroxymethylglutaryl flavonoid glycosides. J Nat Prod. 2009; 72: 1352-4.
4. Hwang JT, Kwon DY, Yoon SH. AMP-activated protein kinase: a potential target for the diseases prevention by natural occurring polyphenols. N Biotechnol. 2009; 26: 17-22.
5. Leopoldini M, Malaj N, Toscano M et al. On the inhibitor effects of bergamot juice flavonoids binding to the 3-hydroxy-3-methylglu-taryl-CoA reductase (HMGR) enzyme. J Agric Food Chem. 2010: 58; 10768-73.
6. Mollace V, Sacco I, Janda E et al. Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitoterapia. 2011; 82: 309-16.
7. Capomolla AS, Janda E, Paone S et al. Atherogenic Index Reduction and Weight Loss in Metabolic Syndrome Patients Treated with A Novel Pectin- Enriched Formulation of Bergamot Polyphenols Nutrients. 2019; 11(6): 1271.
8. Gliozzi M, Walker R, Muscoli S et al. Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. Int J Cardiol. 2013; 170(2): 140-5.
9. Gliozzi M, Carresi C, Musolino V et al. The Effect of Bergamot-Derived Polyphenolic Fraction on LDL Small Dense Particles and Non Alcoholic Fatty Liver Disease in Patients with Metabolic Syndrome. Adv Biol Chem. 2014; 4: 129-37.
10. Mollace V, Malara N, Gratteri S et al. Bergamot polyphenolic fraction counteracts erectile dysfunction occurring in patients suffering from type 2 diabetes. PharmaNutrition. 2016; 4S: S41-S6.
11. Lauro F, Ilari S, Giancotti LA et al. The protective role of bergamot polyphenolic fraction on several animal models of pain. PharmaNutrition. 2016; 4S: S35-S40.
12. Nisticò SP, Bottoni U, Gliozzi M et al. Bergamot polyphenolic fraction counteracts photoageing in human keratinocytes. PharmaNutrition. 2016; 4S: S32-S4.
13. Carresi C, Gliozzi M, Giancotta C et al. Studies on the protective role of Bergamot polyphenols in doxorubicin-induced cardiotoxicity. Pharma- Nutrition. 2016; 4S: S19-S26.
14. Lin CC, Li TC, Lai MM. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol. 2005; 153: 679-86.
15. Mamcarz A, Barylski M, Wełnicki M (ed). Lipidologia. Wydawnictwo Lekarskie PZWL, Warszawa 2021.
16. Musa‑Veloso K, Poon TH, Elliot JA et al. A comparison of the LDL‑cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta‑analysis of randomized, placebo‑controlled trials. Prostaglandins Leukot Essent Fatty Acids. 2011; 85: 9-28.
17. Pirro M, Vetrani C, Bianchi C et al. Joint position statement on „Nutraceuticals for the treatment of hypercholesterolemia” of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA). Nutr Metab Cardiovasc Dis. 2017; 27: 2-17.
18. Reiner Z, Tedeschi‑Reiner E, Romic Z. Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and C‑reactive protein in hypercholesterolaemic patients. Clin Drug Investig. 2005; 25: 701-7.
19. Lan J, Zhao Y, Dong F et al. Meta‑analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015; 161: 69-81.
20. Dewell A, Hollenbeck PL, Hollenbeck CB. Clinical review: a critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations. J Clin Endocrinol Metab. 2006; 91: 772-80.
21. Sahebkar A, Pirro M, Banach M et al. Lipid-lowering activity of artichoke extracts: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2018; 58(15): 2549-56.
22. Ried K, Toben C, Fakler P. Effect of garlic on serum lipids: an updated meta-analysis. Nutr Rev. 2013; 71: 282-99.